A Win-Win Multiple Sclerosis Deal? – Biogen Idec Inc. (BIIB), Elan Corporation, plc (ELN)

Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion. Investors are cheering Biogen and booing Elan based on the changes in their valuations today.

Seems about right to me.

Gaining full rights to the drug is a great move for Biogen. In addition to the upfront payment, Biogen owes a royalty of 12% for the first year, 18% on the first $2 billion in sales in subsequent years, and 25% on sales above $2 billion. But even with those payments, Biogen expects the deal to add $0.20 to $0.30 per share to the bottom line this year.

Biogen Idec Inc (NASDAQ:BIIB)More importantly, having full control over the sales and marketing of the drug should help Biogen’s overall business plan. The company also sells the multiple sclerosis drug Avonex and should have an oral drug for the condition — BG-12, to be sold under the brand name Tecfidera — approved by the Food and Drug Administration shortly.

The ability to coordinate promotion of the three drugs should minimize the cannibalization of sales, except when it makes sense for the company, and maximize the fight with Novartis AG (ADR) (NYSE:NVS)‘ Gilenya and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)s‘ Copaxone, its major competition in the oral and injected space respectively. Both Novartis and Teva should be very worried about how much stronger this deal has made Biogen.

The deal also gives Biogen full control over its own destiny. The biotech put itself up for sale in 2007, but couldn’t find a buyer, likely because a change in control gave Elan the ability to buy the rights to Tysabri away from a potential suitor. With that part of the partnership abolished, Biogen is more attractive as a takeout target.

On the surface, the deal isn’t that bad for Elan. Freeing up the change-in-control provision also makes it a more attractive takeout candidate, and Elan now has a sizable chunk of cash to stock its pipeline with.

The latter is likely what’s worrying investors. Management hasn’t exactly been the best steward of the company’s cash. Use of private jets, for instance, have been a sore subject with investors, especially as the drugmaker laid off workers.

This could be a win-win deal if Tysabri sales continue to grow and Elan makes good use of its new-found wealth. The former seems likely, but I think investors are right to be questioning the latter.

The article A Win-Win Multiple Sclerosis Deal? originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!